SPOP mutation leads to genomic instability in prostate cancer
Gunther Boysen,
Christopher E Barbieri,
Davide Prandi,
Mirjam Blattner,
Sung-Suk Chae,
Arun Dahija,
Srilakshmi Nataraj,
Dennis Huang,
Clarisse Marotz,
Limei Xu,
Julie Huang,
Paola Lecca,
Sagar Chhangawala,
Deli Liu,
Pengbo Zhou,
Andrea Sboner,
Johann S de Bono,
Francesca Demichelis,
Yariv Houvras,
Mark A Rubin
Affiliations
Gunther Boysen
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States; Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom; The Royal Marsden, London, United Kingdom
Christopher E Barbieri
Department of Urology, Weill Cornell Medical College, New York, United States; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, United States
Davide Prandi
Centre for Integrative Biology, University of Trento, Trento, Italy
Mirjam Blattner
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Sung-Suk Chae
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Arun Dahija
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Srilakshmi Nataraj
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Dennis Huang
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Clarisse Marotz
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Limei Xu
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Julie Huang
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Paola Lecca
Centre for Integrative Biology, University of Trento, Trento, Italy
Sagar Chhangawala
Department of Surgery, Weill Cornell Medical College, New York, United States; HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States
Deli Liu
Department of Urology, Weill Cornell Medical College, New York, United States; HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States
Pengbo Zhou
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States
Andrea Sboner
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States; HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States; Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States
Johann S de Bono
Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom; The Royal Marsden, London, United Kingdom
Francesca Demichelis
Centre for Integrative Biology, University of Trento, Trento, Italy; HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medical College, New York, United States; Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States
Yariv Houvras
Department of Surgery, Weill Cornell Medical College, New York, United States; Department of Medicine, Weill Cornell Medical College, New York, United States
Mark A Rubin
Department of Urology, Weill Cornell Medical College, New York, United States; Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College, New York, United States; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, United States; Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, United States
Genomic instability is a fundamental feature of human cancer often resulting from impaired genome maintenance. In prostate cancer, structural genomic rearrangements are a common mechanism driving tumorigenesis. However, somatic alterations predisposing to chromosomal rearrangements in prostate cancer remain largely undefined. Here, we show that SPOP, the most commonly mutated gene in primary prostate cancer modulates DNA double strand break (DSB) repair, and that SPOP mutation is associated with genomic instability. In vivo, SPOP mutation results in a transcriptional response consistent with BRCA1 inactivation resulting in impaired homology-directed repair (HDR) of DSB. Furthermore, we found that SPOP mutation sensitizes to DNA damaging therapeutic agents such as PARP inhibitors. These results implicate SPOP as a novel participant in DSB repair, suggest that SPOP mutation drives prostate tumorigenesis in part through genomic instability, and indicate that mutant SPOP may increase response to DNA-damaging therapeutics.